[hider=ISSOco]

[center][b]The Iris-Sakamoto Corporation[/b][/center]

In 2030, the UK based Iris Medical Technologies and the Japanese based Sakamoto Group merged together and form the Iris-Sakamoto Corporation. The company’s vision was to create a international medical corporation that, with the help of cutting edge technology, would build a better world for tomorrow if by building a better world it meant building a bigger bank account for its investors. In its early days the company was known for following the letter of the law to help with its expansion, driving up prices through handshake deals without forming actual monopolies or lobbying to gain political support for their goods without directly bribing politicians. Thanks to their strong legal team, the company managed to tread the line of legality fairly unscathed.

Still, by 2050 the corporation was almost universally hated by human rights activist and other bleeding hearts, but it wasn’t until their stock started to dip that they did anything to change their methods. Once it hit red the board replaced its CEO, rebranded its vision, and renamed itself to ISSOco. The new CEO, Ingrid Robertson, was a young, charismatic, public-facing figure that gave off the persona of a visionary, openly admitting to the company’s past mistakes and promising to do better in the future through a series of very explicit interviews. A number of charities were formed under her leadership and overall she improved the public’s impression of the company, although little actually changed when it came down to how it conducted business.

[center][b]Personnel & Structure[/b][/center]

ISSOco is a medium sized medical corporation with joint headquarters located in both London and Tokyo as well as a number of research labs and factories located in Cape Town, Tehran, Hong Kong, and Sopahn. They employ around 100,000 people worldwide, from legal and sales to research and security. They are a publicly traded company that is run by a board of twelve individuals split between the two HQs. Since the switch in CEOs, the company has begun to provide employees with housing and transportation on top of their salary, and most employees report a high-level of job satisfaction. 

ISSOco contracts are notably dense and fairly restrictive, and employees are very discreet when it comes to their work. The corporation is broken up into various levels of access. Level 1 Access is for the baseline employees, giving entry only into public areas and the floors focused on sales, HR, and IT. Level 2 Access is broken up into three separate divisions: 2A is for legal, 2B is for security, and 2C is for research. Level 3 Access is restricted to board members and people chosen by their discretion.

[center][b]Resources, Relationships, & Associations[/b][/center]

The company has pulled in quite a bit of assets from its past predatory business practices, and the charities they now run are also for-profit and add a little bit of revenue to the company’s coffers. However, they still largely make most of their profit through selling medical supplies and technology to hospitals, although in the past few years they have begun to branch out and sell supplies directly to consumers. Occasionally they will partner with governments or other businesses, but largely they operate independently. The company has a few factories that allow them to produce some of their materials, but largely they partner with local distributors to lower cost and “support local economy”. 

Part of the reason that they have begun to sell directly to consumers is because the company’s past actions of price gouging and having a negative reputation has slightly burned them when it comes to dealing with some medical conglomerates. This is largely true when it comes to the West. Their market in Europe is fairly small and their presence in the Americas is almost nonexistent. Therefore, the company has shifted its focus to the developing world and has doubled-down on its African and Asian markets, selling cheaply produced and highly marketed over-the-counter antidepressants, cold medicine, skin injections, and “male enhancements in addition to the various projects its research teams are working on. As of late, they have recently begun business talks with various private security companies and military tech developers. [/hider]